Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, CATALYST PHARMACEUTICALS, INC. reported revenue of $589M, up 19.8% year over year. Operating margin was 43.8% and net margin 36.4%, on a free-cash-flow margin of 35.4% with capital expenditure at 0.0% of revenue. Every figure is computed directly from CPRX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $589M | 43.8% | 36.4% |
| FY2024 | $492M | 39.7% | 33.3% |
| FY2023 | $398M | 21.8% | 17.9% |
| FY2022 | $214M | 47.5% | 38.8% |
| FY2021 | $141M | 37.2% | 28.0% |
How does CPRX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.